The USA federal Fiscal Year (FY) 2017 Budget eliminates funding ($13.2 million) for the entire Prostate Cancer program at the Centers for Disease Control (CDC). Malecare asks for your advocacy for restoring that funding. Click here to help out http://malecare.org/advocacy/cdc-prostate-cancer-2017/ The CDC has produced dynamic prostate cancer research, particularly focused on underserved populations such as African American men, and on improving doctor - patient communication. However, you should also be aware that the CDC, just like other federal agencies, follow the prostate cancer screening recommendations set forth by the U.S. Preventive Services Task Force, which recommends against PSA based screening for [...]
I recently returned home from the American Association of Cancer Researchers (AACR) annual meeting held in New Orleans, La. The meeting was, as usual fantastic, but this years conclusion was by far the best I have experienced. The meeting’s closing session was reserved for remarks about the cancer "moonshot" initiative from Vice President Joe Biden. Biden had initially talked about a moonshot for cancer following the death of his son Beau from stage 4 glioblastoma last year, but it was President Obama who formally announced it as a national priority at the State of the Union address in January and [...]
Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.
We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to evaluate tumor response, adverse effects, and survival in men with castrate resistant prostate cancer who had exhausted all other potential approved therapies, evaluated the novel radioligand therapy with Lu-PSMA-617. Fifty therapies using Lu-PSMA-617 were performed in 28 consecutive men with mCRPC. Data were retrospectively analyzed [...]
Increasingly, we are seeing younger men diagnosed with prostate cancer and with bone metastases. One of the more common therapies, radiotherapy is recognized for its effect on local control of bone metastases, but whether it could prolong overall survival, the gold standard is still controversial. Researchers retrospectively evaluated 113 men with prostate cancer and bone metastases who were younger than 70 years of age to see if radiotherapy extended their survival. They found that the 1-, 2-, 3-, 5-, 7- and 10-year survival rates showed no significant difference between a control group and those who had radiotherapy. They did find [...]
The decision to enroll in a clinical trial should involve a discussion between the person with prostate cancer and that individual’s physician. Your participation should depend on many factors, including your motivation for enrolling in a trial, the stage of your prostate cancer, and the trials available and its phase. When you decide to enroll in a clinical trial it is important to fully understand the trial, your possible benefits as well as any possible risks you might experience. As a first step in making a decision to participate in a trial you need to have a comprehensive conversation with your individual doctor [...]